Maria Pia Sormani
Università degli Studi di Genova
H-index: 103
Europe-Italy
Top articles of Maria Pia Sormani
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Biometry extraction and probabilistic anatomical atlas of the anterior Visual Pathway using dedicated high-resolution 3-D MRI | Scientific Reports | Emanuele Pravatà Andrea Diociasi Riccardo Navarra Luca Carmisciano Maria Pia Sormani | 2024/1/3 |
The Safety Profile of Fenebrutinib in Patients with Multiple Sclerosis Is Consistent with Those in Previously Studied Autoimmune Indications (P9-6.012) | Jiwon Oh Anastasiia Raievska Malgorzata Sierzega João Cerqueira Claire S Riley | 2024/4/14 | |
Creating an automated tool for a consistent and repeatable evaluation of disability progression in clinical studies for Multiple Sclerosis. | medRxiv | Noemi Montobbio Luca Carmisciano Alessio Signori Marta Ponzano Irene Schiavetti | 2024 |
NEDA-3 achievement in early highly active relapsing remitting multiple sclerosis patients treated with Ocrelizumab or Natalizumab | Multiple Sclerosis and Related Disorders | Elisabetta Signoriello Alessio Signori Giacomo Lus Giuseppe Romano Girolama Alessandra Marfia | 2024/4/6 |
Therapeutic choices and disease activity after 2 years of treatment with cladribine: An Italian multicenter study (CladStop) | European Journal of Neurology | Irene Schiavetti Alessio Signori Angela Albanese Jessica Frau Eleonora Cocco | 2024/3/28 |
Diagnostic performance of cortical lesions and the central vein sign in multiple sclerosis | JAMA neurology | Alessandro Cagol Rosa Cortese Muhamed Barakovic Sabine Schaedelin Esther Ruberte | 2024/2/1 |
Therapeutic lag: Is treatment effect delayed in progressive MS? | Multiple Sclerosis Journal | Noemi Montobbio Francesca Bovis Alessio Signori Marta Ponzano Irene Schiavetti | 2024/4/14 |
Emulating randomised clinical trials in relapsing-remitting multiple sclerosis with non-randomised real-world evidence: an application using data from the MSBase Registry | Journal of Neurology, Neurosurgery & Psychiatry | Alessio Signori Marta Ponzano Tomas Kalincik Serkan Ozakbas Dana Horakova | 2024/1/19 |
Attention to Sex as a Biological Variable in Phase III Neurological Trials Before and After the 2017 NIH Amendment: a Systematic Review in MS (P4-6.001) | Ayushi Balan Riley Bove Maria Pia Sormani Maria Houtchens | 2024/4/14 | |
Assessing the duration of EDSS improvement after a therapy start: A novel approach applied to the long-term extension of the PRISMS study | Multiple Sclerosis and Related Disorders | Alessio Signori Francesca Bovis Irene Schiavetti Marta Ponzano Mark S Freedman | 2023/11/1 |
Dimethyl fumarate delays multiple sclerosis in radiologically isolated syndrome | Annals of neurology | Darin T Okuda Orhun Kantarci Christine Lebrun‐Frénay Maria Pia Sormani Christina J Azevedo | 2023/3 |
Health related quality of life in the domain of physical activity predicts confirmed disability progression in people with relapsing remitting multiple sclerosis | Multiple Sclerosis and Related Disorders | Gianmarco Abbadessa Marta Ponzano Floriana Bile Giuseppina Miele Alessio Signori | 2023/7/1 |
Reduction in grey matter atrophy in patients with relapsing multiple sclerosis following treatment with cladribine tablets | European Journal of Neurology | Rosa Cortese Marco Battaglini Maria Pia Sormani Ludovico Luchetti Giordano Gentile | 2023/1 |
Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and … | The Lancet Diabetes & Endocrinology | Massimo Terzolo Martin Fassnacht Paola Perotti Rossella Libé Darko Kastelan | 2023/10/1 |
Enhancing diversity of clinical trial populations in multiple sclerosis | Ruth Ann Marrie Jeremy Chataway Barbara E Bierer Marcia Finlayson Elena H Martinez-Lapiscina | 2023/8 | |
Treatment Effect on Brain Atrophy Correlates with Treatment Effect on Cognition in Multiple Sclerosis | Annals of neurology | Maria Pia Sormani Irene Schiavetti Marta Ponzano Elisa Colato Nicola De Stefano | 2023/11 |
Clinical and MRI measures to identify non-acute MOG-antibody disease in adults | Brain | Rosa Cortese Marco Battaglini Ferran Prados Alessia Bianchi Lukas Haider | 2023/6 |
Alemtuzumab-Related Lymphocyte Subset Dynamics and Disease Activity or Autoimmune Adverse Events: Real-World Evidence | Journal of Clinical Medicine | Elisabetta Signoriello Giacomo Lus Francesco Saccà Marco Puthenparampil Cinzia Coppola | 2023/2/22 |
Heterogeneity on long-term disability trajectories in patients with secondary progressive MS: a latent class analysis from Big MS Data network | Journal of Neurology, Neurosurgery & Psychiatry | Alessio Signori Johannes Lorscheider Sandra Vukusic Maria Trojano Pietro Iaffaldano | 2023/1/1 |
Author response: Clinical trials of disease-modifying agents in pediatric MS: Opportunities, challenges, and recommendations from the IPMSSG | Emmanuelle Waubant Brenda Banwell Evangeline Wassmer Maria Pia Sormani Maria Pia Amato | 2023/8/9 |
Co-Authors
